Product image of Miglustat Dipharma (Miglustat) supplied by GNH India

Miglustat Dipharma

Active Ingredient:
Miglustat
Origin:
EU

Miglustat Dipharma (Miglustat)

Miglustat, the active ingredient in Miglustat Dipharma, is a glucosylceramide synthase inhibitor presented as an oral tablet for oral use. It treats Gaucher disease type 1 and Niemann‑Pick disease type C in appropriate patients.

GNH India supplies Miglustat Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Dipharma Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Miglustat is used as substrate reduction therapy for lysosomal storage disorders, targeting glycosphingolipid synthesis.

  • Gaucher disease type 1: reduces accumulation of glucocerebroside, improving hematologic and organ manifestations.
  • Niemann‑Pick disease type C: decreases glycosphingolipid synthesis, supporting neurological and systemic symptom management.
  • Lysosomal storage disorders: provides substrate reduction therapy for applicable conditions.

How It Works

  • Miglustat inhibits the enzyme glucosylceramide synthase, the first step in glycosphingolipid biosynthesis. By blocking this pathway, the drug lowers the production of glucosylceramide and related glycolipids, reducing substrate accumulation within lysosomes and thereby mitigating the pathological effects of storage disorders.

Side Effects

Miglustat may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Diarrhea: loose stools often occurring early in therapy.
  • Nausea: feeling of sickness or upset stomach.
  • Weight loss: unintended reduction in body weight.
  • Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

  • Pancreatitis: inflammation of the pancreas requiring immediate medical attention.
  • Severe allergic reactions: rash, swelling, or anaphylaxis.
  • Hepatotoxicity: elevated liver enzymes indicating potential liver injury.

Precautions & Warnings

Before prescribing Miglustat, clinicians should consider several safety aspects.

  • Renal function: monitor creatinine clearance in patients with kidney disease.
  • Liver function: assess hepatic enzymes before initiating therapy.
  • Pregnancy: safety not established; avoid use unless benefits outweigh risks.
  • Concomitant medications: evaluate potential interactions with oral antidiabetics.
  • Patient counseling: advise on possible gastrointestinal upset and importance of adherence.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Miglustat can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce miglustat exposure, compromising efficacy.
  • Concurrent use with high‑dose oral antidiabetics: can increase risk of hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours.
  • Warfarin: may require INR monitoring due to potential effect on coagulation.
  • Contraceptive steroids: may have altered plasma levels; monitor effectiveness.

Frequently Asked Questions

Miglustat Dipharma is indicated for the treatment of Gaucher disease type 1 and Niemann‑Pick disease type C, both of which are lysosomal storage disorders that benefit from substrate reduction therapy.

Miglustat inhibits glucosylceramide synthase, the enzyme responsible for the first step in glycosphingolipid synthesis. This reduces the production of glucosylceramide and related lipids, decreasing their accumulation in lysosomes and helping to alleviate disease manifestations.

The dosage of Miglustat Dipharma is determined by the prescribing physician based on the patient’s condition, age, weight, and renal function. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of miglustat in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miglustat is a small‑molecule glucosylceramide synthase inhibitor, whereas alternatives such as eliglustat target the same pathway but differ in metabolism, dosing frequency, and drug‑interaction profiles. Choice of therapy depends on patient-specific factors, including liver function, concomitant medicines and tolerability.

Miglustat Dipharma should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it out of direct sunlight to maintain stability.

Miglustat Dipharma is taken orally, usually with a glass of water. The exact timing relative to meals or other medications should follow the prescriber’s guidance to optimize absorption and minimize gastrointestinal side effects.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and hepatotoxicity indicated by elevated liver enzymes. Patients should seek immediate medical attention if they experience severe abdominal pain, rash, swelling, or jaundice.

Miglustat is contraindicated in patients with known hypersensitivity to the drug, those with severe renal impairment, and individuals for whom the risk–benefit assessment is unfavorable, such as certain pregnant or breastfeeding women without a clear therapeutic need.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Miglustat

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT